stooocks.com

Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.

Ovid Therapeutics Inc.

United States · NASDAQ: OVID · Market cap: · P/E: · P/S:

Ovid Therapeutics develops small molecule medicines for brain disorders, epilepsies, and seizure-related neurological conditions.

Ovid Therapeutics is a small biotech company trying to build better drugs for people whose brains misfire. Its focus is epilepsy and other seizure-related neurological disorders — conditions where existing medicines often fail to control seizures or come with side effects that make daily life hard. Ovid's bet is that a newer class of small molecule drugs can calm an overexcited brain without flattening the rest of the person.

Ovid Therapeutics Inc. (OVID) OV329: line art illustration of A small molecule drug vial labeled OV329 with its chemical structure drawn beside it
OV329
OV329 is an experimental drug Ovid is developing for brain disorders.

Its lead program is a drug called soticlestat, which it developed to reduce seizures in rare, hard-to-treat epilepsies such as Dravet syndrome and Lennox-Gastaut syndrome. Ovid licensed the drug to Takeda in a deal that let the bigger Japanese drugmaker run the expensive late-stage trials, while Ovid kept a share of future profits and milestone payments. That structure matters: Ovid is a tiny company that cannot afford to run huge global trials alone, so it trades some upside for cash and a partner's muscle. Ovid makes money not from selling pills yet, but from deals — upfront payments, milestone payments, and royalties if a partner's drug reaches the market. That means the company's fortunes hinge on clinical trial results and regulatory decisions made largely by others. If soticlestat succeeds, Ovid collects a slice; if it fails, the pipeline story weakens fast. Biotech like this is a high-risk, binary business, and Ovid's share price swings on trial news rather than on steady sales.


The company is based in New York and is small enough that a single program can decide its future. Investors in Ovid are essentially betting on neuroscience drug development paying off — a field where many big companies have stumbled. That is the honest picture: a lean, partnership-dependent biotech with one important horse in the race, not a commercial drugmaker with revenue to fall back on.

Saved answer · last researched 16 Nov 2026